Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Selected for European Kindergarten Lighting to Support Children’s Learning and Eye Health
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that LED Luks , a European manufacturer of LED luminaires, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs for private kindergarten facilities’ lighting in Slovenia to support children’s learning and eye health.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005912/en/
(Fig.1) SunLike natural spectrums for Morning – Noon – Evening Colors (Graphic: Business Wire)
In cooperation with LED Luks, Seoul Semiconductor has developed the optimal SunLike Series LED designs based on the natural spectrum light source for the lighting. With SunLike Series natural spectrum LED technology, LED Luks has used lighting brand “ARUN” to support children’s concentration and relaxation with an optimal smart solution for remotely and automatically adjusting the color temperature and dimming representing the light from noon to evening.
The light in noon color mode helps children’s brains more alert and also improve academic performance. The light in the evening color mode makes them more creative and feel relaxed. It also provides high sleep quality by promoting melatonin, thus encouraging the production of growth hormone and boosting memory and immunity. Human body produces growth hormone up to 80% of the daily GH production during sleep. Deep, non-REM sleep helps human brain to wash away waste and to regenerate cells, supporting immunity.
Earth is estimated to be 4.5 billion years old. With natural sunlight, under which all animals on the earth have evolved over 3.9 billion years, plants over 450 million years, insects over 360 million years, and humans over 7 million years. Based on circle of day – month – year, human’s DNA has evolved and a circadian rhythm is internal process that regulates the sleep-wake cycle based on 24-hour body clock that natural sunlight affects.
SunLike Series LEDs are the world’s first technology and have been recognized as an innovative technology that produces light that closely matches the spectrum of natural sunlight by a total of ten global lighting awards held in Korea, Europe, China, and the US over the past three years. Based on the results of a comprehensive sleep study conducted by Professor Christian Cajochen and his colleagues at the University of Basel in Switzerland, LED light sources with the same measured intensity and correlated color temperature (CCT), but different spectral output, can have different effects on human behavior and physiology. The study, published in the Journal of Lighting & Research Technology on March 24, 2019, found “evidence that daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.” According to the results of a study done by the Bio-Information Laboratory of Seoul National University Hospital in July of 2018, SunLike Series natural spectrum LEDs have been shown to reduce eye discomfort and improve sleep patterns. In addition, Seoul Semiconductor has been conducting experiments on protection from myopia and students’ learning and concentration with influential university research teams in Europe and the US for three years, and is expected to announce the study results in the second half of 2020.
“Young people who spend long hours of indoor study and the lack of exposure to daylight particularly need to use a better quality of LED lighting which closely matches natural spectrum of sunlight,” said Carlo Romiti, Europe sales Vice President of Seoul Semiconductor. “We believe that Seoul Semiconductor’s SunLike Series natural spectrum LEDs will be necessary technology for human-centric lighting to support human health, well-being and better performance of daily life, children’s healthy growth as well with three beneficial effects in contrast to conventional LEDs: Better Study, Better Eye Health and Better Immunity.”
Introduced in June 2017, the SunLike Series natural spectrum LEDs are an advanced light source that combine the latest optical and compound semiconductor technology of Seoul Semiconductor with Toshiba Materials’ TRI-R® technology. TRI-R, supported by Toshiba Materials, finds in the definition “The light closest to the sun for human well-being” its original concept. The sunlight spectrum is developed by the same company and can be reproduced by a white LED light source technology. TRI-R is a registered trademark by the Toshiba Materials Co., LTD.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phone, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en.
Seoul Semiconductor Co., Ltd.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 20201.12.2020 18:01:00 EET | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients. Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity
Andersen Global Adds Collaborating Firm in Azerbaijan1.12.2020 17:30:00 EET | Press release
Andersen Global expands into Azerbaijan by way of a Collaboration Agreement with independent Baku-based law firm MGB Law Offices, adding coverage and positioning the organization for further expansion between Europe and Asia. Founded in 1995, MGB Law Offices, which has ten lawyers, has been recognized by IFLR1000, Legal500 and Chambers and Partners as the leading law firm in Azerbaijan. Led by Managing Partner Ismail Askerov, the full-service firm offers solutions in various industries such as oil and gas, aviation, banking and finance, insolvency and restructuring, tax, privatization law and foreign investment. The firm’s client base includes blue-chip multinationals, international financial institutions, insurance companies, airlines, telecom companies and other business entities. “We are proud of our ability to consistently deliver best-in-class services, and our comprehensive solutions position us to be one of the most reputable law firms in the market by allowing us to meet the di
Alira Health Achieves AWS Select Consulting Partner Status1.12.2020 17:00:00 EET | Press release
Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced it has recently earned Amazon Web Services (AWS) Select Consulting Partner status. The firm’s newly formed Advanced Analytics practice will leverage AWS’s cloud computing capabilities to provide greater value to clients, providing fully compliant, made-to-measure digital solutions, powered by AWS, that securely enable the use of data generated by the healthcare community and clients’ own internal data. The solutions are provided to customers in the form of Software-as-a-Service (SaaS), seamlessly integrating into existing workflows and designed to support clients in prioritizing research and development (R&D) investments, identifying novel therapeutic areas suitable for corporate business development, and assessing business opportunities. “Technology has the power to solve complex problems and be a transformative tool across the healthcare and life sciences ecosystem,” said
Rimini Street Awarded Three Brazilian Public Sector Contracts to Support Oracle and SAP Enterprise Software Systems1.12.2020 17:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has been awarded three separate contracts to provide enterprise software support to agencies linked to the Legislative, Executive and Judiciary branches of the Brazilian government, specifically the Chamber of Deputies, the Superior Labor Court and APEX Brasil, an independent social service agency. The Brazilian government public procurement processes were put in place to ensure that public sector organizations work with providers in a manner that is transparent, efficient, ensures economy of scales and the best optimization of public resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005501/en/ Rimini Street Awarded Three Brazilian Public Sector Contracts to Support Oracle and SAP Enterp
Market Access Transformation (MAT) Secures First Institutional Funding Led by Silversmith Capital Partners1.12.2020 17:00:00 EET | Press release
Market Access Transformation (MAT), a global healthcare company that uses cutting edge technology to automate and modernize how life sciences companies capture mission-critical insights that drive decision-making across the product lifecycle, today announced a $30 million minority investment from Silversmith Capital Partners, a Boston-based growth equity firm. The investment marks the first time MAT has raised outside capital and will be used to expand the company’s team and accelerate innovation of its product offerings. Founded in 2016, MAT has revolutionized the way Global Payer Market Research is conducted by developing Rapid Payer Response (RPR), the industry’s only on-demand global platform for gathering critical payer insights. In five years, the company has built a client base of more than 45 biopharma and device manufacturers – including all of the Top 10 pharma companies. MAT’s partnership with Silversmith solidifies its market leadership position in providing technology-driv
PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala1.12.2020 17:00:00 EET | Press release
PCI Pharma Services (“PCI” or “the Company”), a leading pharmaceutical and biopharmaceutical global supply-chain solutions provider, today announced the closing of the previously announced acquisition that gives Kohlberg & Company, LLC (“Kohlberg”) a majority stake in the company. Mubadala Investment Company and Partners Group (acting on behalf of its clients) will have minority shares in the Company. This milestone is a key step for PCI, as Kohlberg and Mubadala will be partnering with PCI’s management team, led by CEO Salim Haffar, to continue the Company’s transformation journey. The team will be adding specific capabilities and geographies organically and inorganically to improve PCI’s client experience and enable its clients to bring life-changing biopharmaceutical therapies to market. Leveraging the global growth trends in biologics and specialized drug therapies, future capabilities include sterile fill finish of injectables, expanding high potency and specialized manufacturing,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom